Business Insider
My Markets Watchlist
Markets Stocks

Guardant Health Inc Registered Shs Stock , GH

49.64 -0.35 -0.70%
10:27:10 AM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Wednesday morning 06/25/2025 the Guardant Health Inc Registered Shs share started trading at the price of $50.31. Compared to the closing price on Tuesday 06/24/2025 on BTT of $49.99, this is a gain of 0.63%. There are 123.89 M shares outstanding in Guardant Health Inc Registered Shs, which values the company at $4.84 B.
Is Guardant Health stock a Buy, Sell or Hold? Guardant Health stock has received a consensus rating of buy. The average rating score is and is based on 43 buy ratings, 1 hold ratings, and 0 sell ratings.
What was the 52-week low for Guardant Health stock? The low in the last 52 weeks of Guardant Health stock was 20.08. According to the current price, Guardant Health is 247.21% away from the 52-week low.
What was the 52-week high for Guardant Health stock? The high in the last 52 weeks of Guardant Health stock was 52.75. According to the current price, Guardant Health is 94.10% away from the 52-week high.
What are analysts forecasts for Guardant Health stock? The 44 analysts offering price forecasts for Guardant Health have a median target of 47.86, with a high estimate of 70.00 and a low estimate of 27.00. The median estimate represents a 103.71 difference from the last price of 49.64.

Guardant Health Stock Snapshot

49.56
Bid
1.00
Bid Size
49.73
Ask
1.00
Ask Size
6/25/2025
Date
10:27 AM
Time
11,061.00
Volume
49.99
Prev. Close
50.31
Open
6.01 B
Market Cap in USD
123.89 M
Number of Shares
123.89 M
Total Number of Shares
49.48
Day Low
50.45
Day High
49.64
20.08
52 Week Low
52.75
52 Week High
49.64
0.00
Dividend in USD
0.00
Dividend Yield
95.00
Free Float in %
-3.56
EPS in USD
-1.13
Book Value per Share in USD
-1.95
Cash Flow per Share in USD

Historical Prices for Guardant Health

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Guardant Health Analyst Data

Total Analysts: 44
Buy Ratings: 43 Neutral Ratings: 1 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 27.00 Median: 47.86 Highest: 70.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Guardant Health Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
06/13/25 Mizuho
Maintained Buy $65
05/06/25 Piper Sandler
Maintained Buy $60
05/01/25 Capital Depesche
Maintained Buy $65
05/01/25 Stifel, Nicolaus & Co., Inc.
Maintained Buy $60
05/01/25 Barclays Capital
Maintained Buy $60
05/01/25 TD Securities
Maintained Buy $60
05/01/25 UBS
Maintained Buy $70
04/10/25 Barclays Capital
Maintained Buy $55
04/10/25 Mizuho
Maintained Buy $55
03/26/25 Stephens Inc.
Maintained Buy $55
03/06/25 Morgan Stanley
Maintained Buy $52
02/26/25 Piper Sandler
Maintained Buy $50
02/24/25 Guggenheim
Maintained Buy $56
02/24/25 Capital Depesche
Maintained Buy $60
02/21/25 Goldman Sachs
Maintained Buy $56
02/21/25 Raymond James Financial, Inc.
Maintained Buy $59
02/21/25 J.P. Morgan
Maintained Buy $55
02/21/25 Stifel, Nicolaus & Co., Inc.
Maintained Buy $53
01/28/25 Goldman Sachs
Maintained Buy $49
01/23/25 Barclays Capital
Maintained Buy $60
01/22/25 Guggenheim
Maintained Buy
07/30/24 BTIG Research
Maintained Buy $50
07/18/24 Bank of America Merrill Lynch
Maintained Buy $40
07/17/24 Goldman Sachs
Maintained Buy $32
06/28/24 Guggenheim
Upgraded to Buy $36
06/04/24 Capital Depesche
Maintained Buy $38
06/03/24 Jefferies & Company Inc.
Maintained Buy $32
05/24/24 Stephens Inc.
Maintained Buy $44
04/29/24 Capital Depesche
Maintained Buy $30
04/24/24 Craig-Hallum Capital
Maintained Buy $28
04/15/24 Goldman Sachs
Maintained Buy $28
04/05/24 Guggenheim
Maintained Hold
02/26/24 Piper Sandler
Maintained Buy $30
02/23/24 J.P. Morgan
Maintained Buy $45
02/23/24 Capital Depesche
Maintained Buy $45
01/29/24 Goldman Sachs
Maintained Buy $37
12/14/23 Guggenheim
Maintained Hold
12/13/23 Wolfe Research
Maintained Hold
11/13/23 Raymond James Financial, Inc.
Upgraded to Buy $27
11/08/23 Morgan Stanley
Maintained Buy $50
10/23/23 Goldman Sachs
Maintained Buy $45
10/20/23 Goldman Sachs
Maintained Buy $45
10/02/23 Citigroup Corp.
Maintained Buy $50
09/28/23 Bernstein
Maintained Buy $34
09/27/23 Piper Sandler
Upgraded to Buy $40
08/08/23 Piper Sandler
Maintained Hold $40
08/07/23 Morgan Stanley
Maintained Buy $55
08/04/23 Citigroup Corp.
Maintained Buy $50

Guardant Health Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 885 1,073 1,323 1,640 1,684
Dividend 0.00 0.00 0.00 0.00 -
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % 0.00 % -
EPS -2.75 -2.33 -1.69 -1.17 -0.93
P/E Ratio -18.15 -21.47 -29.49 -42.72 -53.58
EBIT -434 -386 -287 -257 -113
EBITDA -225 -160 -68 7 17
Net Profit -335 -283 -183 -129 -118
Net Profit Adjusted -255 -205 -148 -52 -
Pre-Tax Profit -319 -274 -178 -141 -109
Pre-Tax Profit Reported -361 -324 -203 16 -
EPS (Non-GAAP) ex. SOE -1.98 -1.54 -1.18 -0.53 -0.96
EPS (GAAP) -2.75 -2.33 -1.69 -1.17 -0.93
Gross Income 556 676 841 1,037 1,068
Cash Flow from Investing 147 -44 -59 -91 -77
Cash Flow from Operations -196 -149 16 180 381
Cash Flow from Financing -47 66 -111 33 -
Cash Flow per Share -1.76 -1.49 -0.82 - -
Free Cash Flow -249 -238 -49 30 -
Free Cash Flow per Share -1.90 -1.97 -0.56 - -
Book Value per Share -3.25 -4.63 -4.15 -1.96 -
Net Debt 232 444 420 -202 -
Research & Development Exp. 326 342 366 382 407
Capital Expenditure 36 41 48 91 77
Selling, General & Admin. Exp. 568 618 688 853 783
Shareholder’s Equity -415 -561 -643 -495 -161
Total Assets 1,223 1,106 1,024 1,224 1,177
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 18 18 19 19
Average Estimate - -0.720 USD -0.701 USD -2.755 USD -2.329 USD
Year Ago - -0.838 USD -0.876 USD -3.555 USD -
Publish Date - 7/31/2025 10/30/2025 - -
Revenue Estimates
No. of Analysts - 20 20 22 22
Average Estimate - 211 USD 226 USD 885 USD 1,073 USD
Year Ago - 177 USD 191 USD 739 USD -
Publish Date - 7/31/2025 10/30/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 739.02 563.95 449.54 373.65 286.73 214.38 90.64
Change of sales in % 31.04 25.45 20.31 30.32 33.75 136.52 81.85
Gross profit on sales 449.22 336.90 291.67 249.39 194.20 143.66 47.43
Gross profit on sales change in % 33.34 15.51 16.95 28.42 35.18 202.88 160.26
Operating income -443.59 -562.52 -534.87 -408.62 -245.25 -81.95 -92.94
Operating income change in % 21.14 -5.17 -30.90 -66.61 -199.27 11.83 -21.32
Income before tax -435.09 -478.76 -653.45 -384.47 -245.90 -69.72 -84.23
Income before tax change in % 9.12 26.73 -69.96 -56.35 -252.69 17.22 -1.21
Income after tax -436.37 -479.45 -654.59 -405.67 -253.78 -75.65 -85.06
Income after tax change in % 8.98 26.76 -61.36 -59.85 -235.47 11.06 -2.21

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 1,625.26 1,627.74 1,549.81 1,559.49 916.19 114.54 62.45
Long-term liabilities per share 11.29 11.69 13.22 13.41 8.48 0.44 0.18
Equity -139.65 158.68 60.18 645.01 1,355.60 847.99 524.95
Equity change in % -188.00 163.68 -90.67 -50.33 62.64 65.25 -
Balance sheet total 1,485.61 1,786.42 1,609.99 2,204.50 2,271.78 962.54 587.40
Balance sheet total change in % -16.84 10.96 -26.97 -2.96 136.02 63.86 71.29

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 6.02 5.04 4.40 3.69 2.94 2.37 2.98
P/E ratio (year end quote, basic EPS) - - - - - - -
P/E ratio (year end quote, diluted EPS) - - - - - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % -9.40 8.88 3.74 29.26 59.67 88.10 89.37
Debt ratio in % 109.40 91.12 96.26 70.74 40.33 11.90 10.63

Guardant Health Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
POTTER MYRTLE S 06/17/2025 26.00 18,154.00 49.47 Sell No
Tariq Musa 06/17/2025 3,213.00 7,190.00 49.47 Sell No
CLARK IAN T 06/16/2025 6,672.00 9,851.00 48.38 Sell No
POTTER MYRTLE S 06/15/2025 2,626.00 18,180.00 49.70 Sell No
Freeman Chris 06/14/2025 2,675.00 46,757.00 49.29 Sell No
Bell Michael Brian 06/14/2025 1,659.00 42,001.00 49.29 Sell No
EAGLE CRAIG 06/14/2025 711.00 35,124.00 49.29 Sell No
Kalia Kumud 06/14/2025 228.00 19,174.00 49.29 Sell No
Saia John G. 06/14/2025 535.00 43,568.00 49.29 Sell No
Saia John G. 06/14/2025 1,020.00 44,103.00 n/a Buy No
EAGLE CRAIG 06/14/2025 1,402.00 35,835.00 n/a Buy No
Kalia Kumud 06/14/2025 637.00 19,402.00 n/a Buy No
POTTER MYRTLE S 06/14/2025 69.00 20,806.00 n/a Buy No
Freeman Chris 06/14/2025 4,879.00 48,030.00 n/a Buy No
Bell Michael Brian 06/14/2025 1,233.00 41,621.00 n/a Buy No
Tariq Musa 06/14/2025 250.00 10,403.00 n/a Buy No
Bell Michael Brian 06/14/2025 2,039.00 43,660.00 n/a Buy No
Freeman Chris 06/14/2025 1,402.00 49,432.00 n/a Buy No
Joyce Meghan V. 06/12/2025 3,337.00 11,150.00 47.22 Sell No
Krognes Steve E. 06/11/2025 6,674.00 17,665.00 n/a Buy No
Tariq Musa 06/11/2025 6,674.00 10,153.00 n/a Buy No
CLARK IAN T 06/11/2025 8,088.00 16,523.00 n/a Buy No
Joyce Meghan V. 06/11/2025 6,674.00 14,487.00 n/a Buy No
POTTER MYRTLE S 06/11/2025 6,674.00 20,737.00 n/a Buy No
Gadde Vijaya 06/11/2025 6,674.00 24,314.00 n/a Buy No

Guardant Health Dividend Calendar

Date Name Dividend *yield Currency
2024 Guardant Health Inc Registered Shs 0.00 0.00 USD
2023 Guardant Health Inc Registered Shs 0.00 0.00 USD
2022 Guardant Health Inc Registered Shs 0.00 0.00 USD
2021 Guardant Health Inc Registered Shs 0.00 0.00 USD
2020 Guardant Health Inc Registered Shs 0.00 0.00 USD
2019 Guardant Health Inc Registered Shs 0.00 0.00 USD
2018 Guardant Health Inc Registered Shs 0.00 0.00 USD
2017 Guardant Health Inc Registered Shs - - USD
2016 Guardant Health Inc Registered Shs - - USD
*Yield of the Respective Date

Guardant Health Calendar

Event Estimate Info Date
Earnings Report -0.720 USD Q2 2025 Earnings Release 07/31/2025
Earnings Report -0.701 USD Q3 2025 Earnings Release 10/30/2025
Earnings Report -0.694 USD Q4 2025 Earnings Release 02/19/2026
Earnings Report -0.656 USD Q1 2026 Earnings Release 04/30/2026

Guardant Health Past Events

Event Actual EPS Info Date
Annual General Meeting -3.560 USD Annual General Meeting 06/18/2025
Earnings Report -0.770 USD Q1 2025 Earnings Release 04/30/2025
Earnings Report -0.900 USD Q4 2024 Earnings Release 02/20/2025
Earnings Report -0.880 USD Q3 2024 Earnings Release 11/06/2024
Earnings Report -0.840 USD Q2 2024 Earnings Release 08/07/2024
Annual General Meeting -4.280 USD Annual General Meeting 06/12/2024
Earnings Report -0.940 USD Q1 2024 Earnings Release 05/09/2024
Earnings Report -1.580 USD Q4 2023 Earnings Release 02/22/2024
Earnings Report -0.730 USD Q3 2023 Earnings Release 11/06/2023
Earnings Report -0.670 USD Q2 2023 Earnings Release 08/03/2023
Annual General Meeting -6.410 USD Annual General Meeting 06/14/2023
Earnings Report -1.300 USD Q1 2023 Earnings Release 05/09/2023
Earnings Report -1.360 USD Q4 2022 Earnings Release 02/23/2023
Earnings Report -1.580 USD Q3 2022 Earnings Release 11/03/2022
Earnings Report -2.250 USD Q2 2022 Earnings Release 08/04/2022
Annual General Meeting -4.000 USD Annual General Meeting 06/15/2022
Earnings Report -1.210 USD Q1 2022 Earnings Release 05/05/2022
Earnings Report -0.890 USD Q4 2021 Earnings Release 02/23/2022

Guardant Health Profile

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
7
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
OSZAR »